

DAFTAR PUSTAKA

1. UNAIDS. UNAIDS fact sheet - Latest statistics on the status of the AIDS epidemic. *End Aids Epidemiology*. 2020;(July):8. doi:2017
2. Kemenkes RI. Infodatin Pusat Data dan Informasi Kementerian Kesehatan RI. Published online 2017:1–12.
3. WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV: Early Release. *Guidel when to start Antiretrovir Ther pre-exposure Prophyl HIV Early Release*. 2016;2(2). doi:10.1097/00022744-199706000-00003
4. KEMENKES. Pedoman Nasional Pelayanan Kedokteran Tata Laksana HIV. 2019;23(3):2019.
5. Page M, Taylor S. Antiretroviral pharmacology. *Med (United Kingdom)*. 2018;46(5):287–292.
6. Mataranyika PA, Kibuule D, Kalemeera F, et al. Liver enzyme elevations in a cohort of HIV/AIDS patients on first-line antiretroviral therapy in Namibia: Findings and implications. *Alexandria J Med*. 2018;54(1):49–56.
7. Deshwal R, Arora S. Serum alanine aminotransferase elevations in HIV positive patients on antiretroviral therapy in India. *J Assoc Physicians India*. 2019;67(March):67–70.

8. James M R, Lower R, Henderson G, et al. Anti Viral Drug. In: James M R, Lower R, Henderson G, Loke YK, Macewan D, ed. *Rang & Dale's Pharmacology*. 9th ed. Elsevier Inc; 2020:678–689.
9. Merati T. Immunopatogenesis Infeksi HIV. In: Setiati S, Alwi I, Sudoyo A, Simadribata M, Setiyohadi B, Syam A, ed. *Buku Ajar Ilmu Penyakit Dalam FK-UI*. 6 ed. ; 2014:902–905.
10. Wecker A. Antiretroviral Drugs for HIV. In: *Brody's Human Pharmacology*. ; 2010:191–203.
11. Brandon Bookstaverh M, Connolly KER, Caulder CR. Antiretroviral Therapy. In: Schafer JJ, Cocohoba JM, Sherman EM, Tseng AL, ed. *HIV Pharmacotherapy: The Pharmacist's Role in Care and Treatment*. 1st ed. ; 2018:25–58.
12. Brenner GM, Stevens CW. Antiviral Drug. In: Brenner GM, Stevens CW, ed. *Pharmacology*. 5th ed. Elsevier Inc; 2018:483–496.
13. Anderson PL, Yager J, Fletcher C V. Human immunodeficiency Virus Infection. In: DiPiro JT, Yee GC, Posey LM, Halnes ST, Nolin TD, Ellingrod VL, ed. *Pharmacotherapy: A Pathophysiologic Approach*. Vol 11. 11th ed. ; 2020:6127–6238.
14. Sani Aliyu. Viral, Fungal, protozoal and Helmintic Infection. In: Bennett PN,

- Brown MH, Sharma P, ed. *Clinical Pharmacology*. 11th ed. Elsevier Inc; 2012:102–103.
15. Arts E. HIV-1 Antiretroviral Drug Therapy. 2014;(April 2012).
 16. Kaspar MB, Sterling RK. Mechanisms of liver disease in patients infected with HIV. 2017;(figure 1):1–7.
 17. Sherman KE, Rockstroh J, Thomas D. HIV and Liver Disease: An Update. *HHS Public Access*. 2015;62(6):1871–1882.
 18. Ganesan M, New-aaron M, Dagur RS, et al. Alcohol Metabolism Potentiates HIV-Induced Hepatotoxicity : Contribution to End-Stage Liver Disease. *Biomolecules*. 2019;9:1–19.
 19. Paula AA, Falcão MCN, Pacheco AG. Metabolic syndrome in HIV-infected individuals : underlying mechanisms and epidemiological aspects. Published online 2013.
 20. Soti S, Corey KE, Lake JE, et al. NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk? 2019;15(3):212–222.
 21. Kardashian A, Ma Y, Scherzer R, et al. Sex differences in the Association of HIV infection with Hepatic Steatosis. 2018;31(3):365–373.
 22. Debes JD, Bohjanen PR, Boonstra A. Mechanisms of Accelerated Liver Fibrosis Progression during HIV Infection. *J Clin Transl Hepatol*. 2016;4:328–335.

23. Chen JY, Chung RT. HCV and HIV Co-infection: Mechanisms and Management. *NIH*. 2015;11(6):362–371.
24. Soriano V, Puoti M, Garcia-Gascó P, et al. Antiretroviral drugs and liver injury. *Aids*. 2008;22(1):1–13.
25. Ezhilarasan D, Srilekha M, Raghu R. HAART and hepatotoxicity. *J Appl Pharm Sci*. 2017;7(4):220–226.
26. Rivera CG, Otto AO, Zeuli JD, et al. Hepatotoxicity of contemporary antiretroviral drugs. *Curr Opin HIV AIDS*. 2021;16(6):279–285.
27. Núñez M. Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management. *J Hepatol*. 2006;44(SUPPL. 1):53–66.
28. Jones M, Núñez M. Liver toxicity of antiretroviral drugs. *Semin Liver Dis*. 2012;32(2):167–176.
29. Bonacini M, Inductivo-Yu I. Highly Active Antiretroviral Therapy-Induced Liver Injury. *Curr Drug Saf*. 2008;3(1):4–13.
30. Abubakar MG, Abduljalil MM, Nasiru YI. Changes in Liver Function Enzymes of HIV/AIDS Patients Treated with Antiretroviral Drugs (ARVS) in Specialist Hospital, Sokoto, Nigeria. *Niger J Basic Appl Sci*. 2014;22(3):85–89.
31. Ikekpeazu EJ, Neboh EE, Maduka IC, et al. Long-Term Effect of Different Classes of Highly Active Antiretroviral Therapy on Transaminases. *J Lab*

Physicians. 2009;1(02):077–081.

32. Qin F, Jiang J, Qin C, et al. Liver damage in patients living with HIV on antiretroviral treatment with normal baseline liver function and without HBV/HCV infection: An 11-year retrospective cohort study in Guangxi, China. *BMJ Open*. 2019;9(4):1–10.
33. Neff GW, Jayaweera D, Sherman KE. Drug-induced liver injury in HIV patients. *Gastroenterol Hepatol*. 2006;2(6):430–437.
34. Androutsakos T, Schina M, Pouliakis A, et al. Causative factors of liver fibrosis in HIV-infected patients. A single center study. *BMC Gastroenterol*. 2020;20(1):1–7.
35. Alghamdi S, Alrbiaan A, Alaraj A, et al. Elevated alanine aminotransferase levels in HIV-infected persons without hepatitis B or C virus coinfection. *Ann Saudi Med*. 2016;36(4):288–291.
36. Achondou AE, Atanga R, Tanlaka EJ, et al. Variation of Serum Transaminases in HIV/AIDS Patients on Different Antiretroviral Regimens, Attending the Saint Elizabeth Hospital, Shisong, Northwest Region, Cameroon. 2017;6(1):6–10.
37. Zeleke A, Misiker B, Yesuf TA. Drug-induced hepatotoxicity among TB/HIV co-infected patients in a referral hospital, Ethiopia. *BMC Res Notes*. 2020;13(1):1–5.

38. Naidoo K, Hassan-Moosa R, Mlotshwa P, et al. High Rates of Drug-induced Liver Injury in People Living With HIV Coinfected With Tuberculosis (TB) Irrespective of Antiretroviral Therapy Timing During Antituberculosis Treatment: Results From the Starting Antiretroviral Therapy at Three Points in TB Tri. *Clin Infect Dis.* 2020;70(12):2675–2682.
39. Achila OO. Assessment of Liver Enzyme Abnormality Among HIV-Infected Patients on Antiretroviral Therapy in Asmara, Ertrea.2022.
40. Osakunor DNM, Obirikorang C, Fianu V, Asare I, Dakorah M. Hepatic enzyme alterations in HIV patients on antiretroviral therapy: A case-control study in a hospital setting in Ghana. *PLoS One.* 2015;10(8):1–10.
41. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: A guide for clinicians. *Cmaj.* 2005;172(3):367–379.
42. Tadesse BT, Foster BA, Kabeta A, et al. Hepatic and renal toxicity and associated factors among HIV-infected children on antiretroviral therapy: a prospective cohort study. *HIV Med.* 2019;20(2):147–156.
43. Gebremicael G, Tola HH, Gebreegziaxier A, et al. Incidence of hepatotoxicity and factors associated during highly active antiretroviral therapy in people living with hiv in ethiopia: A prospective cohort study. *HIV/AIDS - Res Palliat Care.* 2021;13:329–336.

44. Crane M, Iser D, Lewin SR. Human immunodeficiency virus infection and the liver. *World J Hepatol.* 2012;4(3):91–98.
45. Tesfa E, Siefu D, Belayneh Y, et al. Liver enzyme elevation in patients taking HAART compared with treatment naïve controls at Debre Berhan Referral Hospital: A comparative cross-sectional study, Northeast Ethiopia. *BMC Res Notes.* 2019;12(1):1–7.
46. Mata-Marín JA, Gaytán-Martínez J, Grados-Chavarría BH, et al. Correlation between HIV viral load and aminotransferases as liver damage markers in HIV infected naïve patients: A concordance cross-sectional study. *Virol J.* 2009;6:4–7.
47. Chen J, Li W, Huang X, et al. Evaluating Total Lymphocyte Count as a Surrogate Marker for CD4 Cell Count in the Management of HIV-Infected Patients in Resource-Limited Settings: A Study from China. *PLoS One.* 2013;8(7):4–9.
48. Agbecha A, Ikyernum JA. Impact of HIV-Infection on Serum Liver Enzymes: A Comparative Study among Anti-retroviral Therapy (ART) Naïve Patients, ART Follow-Up Patients, and HIV Sero-negative Controls. *Int J Healthc Med Sci.* 2018;4(12):196–200.
49. Peluso MJ, Colby DJ, Pinyakorn S, et al. Liver function test abnormalities in a longitudinal cohort of Thai individuals treated since acute HIV infection. *J Int*

AIDS Soc. 2020;23(1).

50. Denué BA, Bello HS, Mshelia HH. Correlation between HIV viral load and alanine aminotransferase (ALT) as marker of liver damage in HIV infected naive patients in North-eastern Nigeria. *J AIDS HIV Res.* 2013;5(8):306–310.
51. Yimer G, Gry M, Amogne W, et al. Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: A prospective four arm observational study in Ethiopian patients. *PLoS One.* 2014;9(4).
52. Sulkowski MS. Drug-Induced Liver Injury Associated with Antiretroviral Therapy that Includes HIV-1 Protease Inhibitors. *Clin Infect Dis.* 2004;38(SUPPL. 2).
53. Iddi S, Minja CA, Silago V, et al. High Human Immunodeficiency Virus (HIV) Viral Load and Coinfection with Viral Hepatitis Are Associated with Liver Enzyme Abnormalities among HIV Seropositive Patients on Antiretroviral Therapy in the Lake Victoria Zone, Tanzania. *AIDS Res Treat.* 2019;2019.
54. Akekawatchai C, Sretapunya W, Pipatsatitpong D, et al. Hepatitis B or C virus coinfection in and risks for transaminitis in human immunodeficiency virus - Infected Thais on combined antiretroviral therapy. *Asian Biomed.* 2015;9(3):353–361.
55. Ndifontaiyong AN, Ali IM, Sokoudjou JB, et al. The effect of hbv/hcv in

response to haart in hiv patients after 12 months in kumba health district in the south west region of cameroon. *Trop Med Infect Dis.* 2021;6(3).